Skip to main content
Equibles

NCEL · NewcelX Ltd.

Track NCEL — free

Use NCEL with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research NCEL.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$2.61 -0.02 (-0.76%) At close · Oct 20
Rebalance outlook locked
Market Cap
$15.08M
Shares
5.78M
Volume · Oct 20 9412 Avg daily vol (3M) 8497

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$2.61 Open$2.72 Day$2.55–3.00 52W close$1.88–16.90 Avg vol 30d6K Short int10K · 0.2% float · 1.6d Short vol40% DataJan 2021–Oct 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
$55,000
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
276.2
Trailing earnings · reciprocal yield 0.4%
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+29.9%
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
0.2%
Latest settlement · 1.6 days to cover
View all 122 metrics

Equibles Rating

blended score · not investment advice
Overall
Strong Sell
SellHoldBuy
Technical Strong Sell Momentum Weak Sentiment Bullish Fundamentals Poor Quant / Vol Very High
Market backdrop VIX 17.3 · elevated Equity put/call 0.56
Technical
price trend
Strong Sell
50 / 200-day cross No cross
Price vs 200-day avg −15%
below
Price vs 50-day avg −17%
below
RSI (14) 39
neutral
MACD trend Negative
52-week position 5%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Weak
1-month return −14%
trailing
6-month return −24%
trailing
YTD return +37%
this year
Relative strength −32%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $3 › 200d $3 — 50d above 200d
Institutional flow Flat
1 of 4 funds reported for Sep 30 · net 0 sh shares
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
0.17% of float · ▼ -34.9% MoM · 1.6 days cover
Volume signal Reversal watch
High volume on a down day — possible exhaustion
Institution breadth Multi-yr high
4 holders — near 2-yr high, broad support
Squeeze score 21
low risk · 0–100
Fundamentals
Poor
EPS growth −11%
Y/Y
Free cash flow $-2.8M
Balance sheet $169.4K
net debt
Quant / Vol
risk profile
Very High
Volatility 112%
annualized · 1-yr
Max drawdown −89%
past year
ATR 11.2%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Strong Sell
4 · 3 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−15% Bearish
Price vs 50-day avg
−17% Bearish
RSI (14)
39 Neutral
MACD trend
Negative Bearish
52-week position
5% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $3 › 200d $3 — 50d above 200d
Institutional flow Flat
1 of 4 funds reported for Sep 30 · net 0 sh shares
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
0.17% of float · ▼ -34.9% MoM · 1.6 days cover
Volume signal Reversal watch
High volume on a down day — possible exhaustion
Institution breadth Multi-yr high
4 holders — near 2-yr high, broad support
Price context
position in its 52-week range
Range low $2 Now $3 · 5% Range high $17
vs 200-day avg -15% vs 50-day avg -17%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
NCEL
NewcelX Ltd.
this stock
$15.08M +37.4% — — 0.2%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $130.07B +13.5% +46.2% 29.9 1.8%
MRNA
Moderna, Inc.
 $96.65B +720.9% +4.3% — 7.7%
REGN
Regeneron Pharmaceuticals, Inc.
 $83.13B +4.6% +20.8% 20.0 2.1%
CSLLY
Csl Ltd
 $66.34B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders
Holders
4
% held
0.2%
Reported
1 of 4
Top holder
HRT FINANCIAL LP
Held Float
View
Short & Settlement
Short Interest Falling
Shares short
9.8K
Days to cover
1.6d
Change
-5.2K sh
View
Short Volume
Short vol %
40%
As of
Oct 20, 2026
Short Total
View
Fails to Deliver
FTD shares
201
Value
$693
As of
Aug 5, 2026
View
Off-Exchange
Off-exchange %
58.4%
Week of
Sep 14, 2026
Off-exch Lit
View
Financials
Financials
Net income (FY)
$-8.3M
EPS diluted
$2.16
View
Filings
SEC Filings
Latest
6-K
Filed
Sep 18, 2026
This year
19
View
Exempt Offerings
Offering
$2.9M
Filed
Aug 24, 2026
View

Performance

5D 20D 120D MTD YTD
NCEL -8.1% -14.0% -23.7% -15.1% +37.4%
SPY -1.2% -0.6% +8.1% +0.8% +12.8%
vs SPY -7.0% -13.5% -31.8% -16.0% +24.6%
Key facts CIK 1783036 CUSIP H5835A109 13F (30d) 1 filings 1 filers Visit website Investor relations